Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$1.89
▲ $0.01 (+0.8%)
Market data updated: 09/23 09:07 AM
News analyzed: 09/23/2026
Market Cap
$189.49M
Day Range
$1.86 - $1.95
52-Week Range
$0.88 - $2.34
Beta
—
Next Earnings
11.11.2026
Support
$1.05
Resistance
$2.34
CRDL is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+69.6% (1Y)
🟡 Moderate
Strengths: 5/14 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Price vs. SMA 50
Price is above the 50-day average
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 6.9% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
Cardiol Therapeutics (CRDL) demonstrates a robust overall investor score of 76, driven primarily by strong technical and news-based momentum. The technical category scores 80, reflecting a clear upward trend with the stock price above both its 50-day and 200-day moving averages, alongside a positive MACD histogram indicating rising momentum. However, the RSI (75.6) and %K (89.3) readings suggest the stock is nearing overbought territory, signaling potential short-term consolidation. Meanwhile, the news category scores even higher at 86, reflecting a surge in positive and neutral coverage, including momentum-driven headlines and comparisons to peer performance, reinforcing investor confidence. The risk category, however, drags the score down to 34 due to high volatility (ATR of 6.1% of price) and a volatile KLT ratio (0.45) with a historical maximum drawdown of 72.7%, indicating significant downside risk if the trend reverses.
The stock price is firmly above both its 50-day and 200-day moving averages, with a positive MACD histogram and strong momentum (ADX 61.7), but RSI and %K readings indicate overbought conditions.
This suggests a strong uptrend with potential for continued gains, though overbought signals may prompt near-term pullbacks.
Recent news coverage is overwhelmingly positive, with multiple articles highlighting momentum and outperforming peer stocks, reinforcing investor enthusiasm.
Positive sentiment can drive sustained buying pressure and validate the stock’s upward trajectory.
The stock exhibits high volatility (ATR 6.1%) and a volatile KLT ratio (0.45) with a historically extreme drawdown of 72.7%, signaling elevated risk.
Such volatility and downside potential could lead to sharp corrections if market conditions shift.
StockIQ conclusion
Cardiol Therapeutics (CRDL) exhibits a compelling combination of technical strength and positive news sentiment, supported by outperformance and momentum indicators. However, elevated volatility and overbought conditions introduce risks of short-term corrections. While the stock’s current trajectory appears favorable, investors should monitor volatility metrics and news developments closely, as these factors could significantly influence future performance.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
as of 09/11/202659
This Week
73
7D Ago
↓ -14
Weakening
Technical
55
7D Ago: 78
↓ -23
News
80
7D Ago: 80
→ 0
Risk
34
7D Ago: 34
→ 0
Biggest Declines
📊 Score History
59
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
5d ago · $1.86
Evidence: Narrative Gap moved from 32 to 6 day-over-day
What happened after
Still awaiting outcome
21d ago · $1.98
Evidence: -3.8pp vs. sector average today
What happened after
22d ago · $1.98
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
22d ago · $1.98
Evidence: 11 bullish / 1 bearish technical signals agreeing
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
59 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 27, 2026
Then
79
$2.14
Now
59
$1.89
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
55
Risk
34
Sentiment
80
Fundamental
No data available
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent coverage of Cardiol Therapeutics has centered on its capital‑raising activities and upcoming trial milestones. In mid‑September the company disclosed that exercising outstanding warrants generated more than US $7 million, extending its cash runway into the first half of 2028 and funding operations through the pivotal Phase III MAVERIC trial readout. It also filed a US $150 million base‑shelf prospectus to enable future equity, debt or warrant offerings, while analysts note potential upside ahead of the make‑or‑break Q1 2027 data readout.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Cardiol Therapeutics Inc. - Class A Common. News trend score: 80. Reason: 7 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
39
🎯 Conviction (vs. Emotion)
50
Psychology
45
Fundamentals
—
Technical
55
Valuation
—
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+84%
Market Narrative
45
Fundamental Reality
50
Narrative Gap
-5
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for CRDL suggests a dominant euphoric state, with traders likely chasing gains driven by strong momentum and extreme overbought conditions. The narrative gap (29 points) indicates optimism exceeds fundamental validation, a classic euphoria trait. Anchoring near resistance (2.5%) hints at potential profit-taking if price stalls. The key question: will traders sustain euphoria or pivot as overbought metrics approach exhaustion?
Updated: 09/09/2026, 02:52 PM
What could change this?
👥 What the crowd believes
"Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?"
"Cardiol Therapeutics is advancing its synthetic cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis"
"Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (CRDL) with a Buy and raises the price target from $8 to $10"
"Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference"
🧠 Market Brain events driving this
📈 16D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 81/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock sparks a stark contrast between Jesse Livermore’s high-scoring, trend-focused approach and the overwhelming caution from the rest of the methodologies. Livermore’s near-perfect score suggests the price action aligns with his documented love for strong upward momentum, while the vast majority of investors—ranging from Graham and Fisher to Marks and Mackay—either lack sufficient data to form a clear opinion or flag serious red flags. The efficient-market camp sees only weak evidence for active picking, while the risk-averse voices like Loeb, Marks, and Nelson warn of overvaluation, stretched cycles, or speculative bubbles. Even the behavioral analysts like Mackay and Housel detect crowd-driven volatility or overbought conditions, leaving only Livermore’s technical optimism as a notable outlier.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 81
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 50
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 48
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 45
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 43
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 41
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 21
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 21
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 284 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (5 bullish · 6 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 7 positive, 11 neutral, 2 negative out of the last 20 articles.
PR Newswire · 16.9.2026
CNW Group · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 14.9.2026
Zacks · 14.9.2026
SeekingAlpha · 12.9.2026
Yahoo · 10.9.2026
CNW Group · 10.9.2026
Benzinga · 10.9.2026
Zacks · 10.9.2026
Yahoo · 10.9.2026
PR Newswire · 9.9.2026
Yahoo · 9.9.2026
CNW Group · 9.9.2026
Benzinga · 26.8.2026
Yahoo · 25.8.2026
Zacks · 25.8.2026
Zacks · 24.8.2026
Yahoo · 24.8.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Cardiol Therapeutics Inc. - Class A Common (CRDL) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for CRDL specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
CRDL's technical score is 55/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Price is above the 50-day average; Price is above the 200-day average; RSI 50.8 — healthy positive momentum.
Based on the real signals StockIQ computed: ATR: 6.9% of price; Calmar: 0.38 (3y annualized return 27.6% / max drawdown 72.7%); MACD histogram is negative — falling momentum.
StockIQ has no recorded dividend payment history for CRDL.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 0 filings.
No recent insider transaction filings found for this stock.
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,927,585 shares short as of 2026-08-31 · vs. 2,252,735 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
52.4% of trading volume this week was short selling, vs. 49.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology